Cowen Healthcare Investments

Investor type Corporate Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 32
Average round size
info
The average size of a deal this fund participated in
$78M
Portfolio companies 28
Rounds per year 6.40
Lead investments 9
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.12
Exits 14
Key employees 2
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

Cowen Healthcare Investments seemed to be an CVC arrangement as part of the organization.

The overall number of key employees were 2.

Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Orchard Therapeutics, Repare Therapeutics, KSQ Therapeutics. We can highlight the next thriving fund investment areas, such as Genetics, Therapeutics. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low.

The standard case for the fund is to invest in rounds with 8-9 partakers. Despite the Cowen Healthcare Investments, startups are often financed by Versant Ventures, F-Prime Capital, Slater Technology Fund. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Versant Ventures, RA Capital Management. In the next rounds fund is usually obtained by Innovate UK, Duchenne UK.

The top amount of exits for fund were in 2019. The common things for fund are deals in the range of 50 - 100 millions dollars. The average startup value when the investment from Cowen Healthcare Investments is 50-100 millions dollars. The important activity for fund was in 2018. The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 2 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this Cowen Healthcare Investments performs on 7 percentage points less the average number of lead investments.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Cowen Healthcare Investments:
Typical Co-investors
Cowen Healthcare Investments is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Cowen Healthcare Investments:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Anchor Group Geneva, Geneve, Switzerland
BKCM New York, New York, United States
Convoy Global Holdings China, Hong Kong, Hong Kong Island
Drexel Hamilton, LLC -
Huaguan Capital -
Israel Biotech Fund Center District, Israel, Rishon Lezion
Nesnah Ventures LLC La Crosse, United States, Wisconsin
Poplar Ventures Kentucky, Louisville, United States
Prelude Trust England, London, United Kingdom
Rockefeller Foundation New York, New York, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Lycia Therapeutics

Biotechnology
Health Care
Life Science
$70M09 Sep 2021 San Diego, California, United States

Larimar Therapeutics

Biotechnology
Medical
Therapeutics
$95M21 May 2021 Lower Merion Township, Pennsylvania, United States

Arch Oncology

Biotechnology
$105M27 Apr 2021 California, United States

Evox Therapeutics

Biotechnology
Health Care
Pharmaceutical
$94M18 Feb 2021 Oxford, England, United Kingdom

Personal Genome Diagnostics

Analytics
Bioinformatics
Biotechnology
Genetics
Health Diagnostics
Medical
$103M10 Feb 2021 Baltimore, Maryland, United States

Delfi Diagnostics

Biotechnology
Health Care
Health Diagnostics
$100M12 Jan 2021 Baltimore, Maryland, United States

Ikena Oncology

Biotechnology
Health Care
Therapeutics
$120M05 Jan 2021 Boston, Massachusetts, United States

Health Care
Medical
$80M16 Dec 2020 San Francisco, California, United States

VectivBio

Biotechnology
Health Care
Medical
$110M19 Oct 2020 Basel, Basel-City, Switzerland
News
Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

Arch Oncology Secures $105M Series C

– Arch Oncology, a clinical-stage immuno-oncology company, has closed a $105m Series C financing co-led by Eventide Asset Management, Cowen Healthcare Investments and current investor 3×5 Partners.
– New investors in the round included Adage Capital Management, Point72 Asset Management, Avego Healthcare Capital, FMB Research and Broadfin Holdings.
– The company’s existing investors, including Roche Venture Fund, RiverVest Venture Partners, and Lightchain also participated in the round.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Cowen Healthcare Investments?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: